Navigation Links
Schering-Plough Announces Presentation of Phase II Trial Results,for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual,Meeting of The American College of Cardiology/i2 Summit

KENILWORTH, N.J., March 12, 2007 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that results of the Phase II trial of its novel oral thrombin receptor antagonist (TRA) SCH 530348 will be presented at the 2007 annual Scientific Sessions of the of Cardiology (ACC.07)/Innovation in Intervention (i2) Summit, March 24-27 in New Orleans. The Phase II trial, referred to as the Thrombin Receptor Antagonist in Percutaneous Coronary Intervention (TRA-PCI) trial, has been accepted as a late-breaker presentation.

The trial was designed to evaluate the safety and tolerability of Schering-Plough's TRA coadminstered with standard of care antithrombotic therapy (including aspirin and clopidogrel) in patients undergoing percutaneous coronary intervention (PCI). A secondary objective was to assess whether patients treated with the compound had fewer cardiovascular events such as heart attack, need for urgent coronary revascularization, or death at 60 days compared with patients treated with the standard of care.

The Phase II trial, with an abstract titled Results of a Multinational, Randomized, Double-Blind, Placebo-Controlled Study of a Novel Thrombin Receptor Antagonist SCH 530348 in Percutaneous Coronary Intervention, will be presented by the TRA-PCI investigators.

About Schering-Plough Corporation

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its approximately 33,500 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.sch ering-plough.com.

CONTACT: Media Contact: Lee A. Davies, +1-908-298-7127; or InvestorContact: Alex Kelly, +1-908-298-7436

Web site: http://www.schering-plough.com/

Ticker Symbol: (:SGP)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016 /PRNewswire/ - Demers Ambulances announces its ... to Okaloosa County Emergency Medical ... III ambulances and one LT2 van. Quality Emergency Vehicles in ... is responsible for the sale.  This is the latest in ... , Executive Vice President at Demers. --> Benoit ...
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent ... der Aufnahme von Patienten für eine Studie zur ... Aneurysmen („WEB") speziell für die Behandlung von rupturierten ... , MD, Leiter der Neuroradiologie an der Universitätsklinik ... und Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten ...
(Date:2/12/2016)... SEOUL, South Korea , Feb. 12, ... Inc. today announced they will form a partnership ... precision medicine in cancer. The goal of the ... technology with Macrogen,s high-throughput Next Generation Sequencing capabilities ... Clinical Laboratory Improvement Amendments (CLIA) of 1988 by ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... , ... Erlanger Agency has announced a new partnership in its ongoing community ... on the fight against breast cancer, fundraising for a local woman named Carmen, who ... Carmen is a loving single mother of two boys who also serves as caregiver ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Donor Network ... northern California and Nevada, announced a partnership with San Ramon Regional Medical Center. Under ... the hospital’s facilities as a way to accommodate a more certain time frame for ...
(Date:2/12/2016)... ... , ... For Coast Dental dentist Everet Lake, DDS, the smiles began at ... shortly before 7 a.m. to volunteer at Friday’s Dentistry from the Heart event in ... to help hundreds of uninsured and underinsured people receive much-needed dental care. , ...
(Date:2/12/2016)... ... 12, 2016 , ... Mediaplanet today announces the launch of ... of “Revolutionizing Cancer Care” is distributed within the February 12 issue of USA ... circulation of approximately 250,000 copies and an estimated readership of 750,000 readers. The ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic Information ... Health Plans and PBMs,” an upcoming Feb. 24 webinar that will discuss ways ... big-dollar therapeutic categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost ...
Breaking Medicine News(10 mins):